Further structural exploration of trisubstituted asymmetric pyran derivatives (2S,4R,5R)-2-benzhydryl-5-benzylamino-tetrahydropyran-4-ol and their corresponding disubstituted (3S,6S) pyran derivatives: A proposed pharmacophore model for high-affinity interaction with the dopamine, serotonin, and norepinephrine transporters

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4239-4247

  Zhang, Shijun ^a   Fernandez, Fernando ^a   Hazeldine, Stuart ^a   Deschamps, Jeffrey ^b   Zhen, Juan ^c   Reith, Maarten E A ^c   Dutta, Aloke K ^a  

^a WAYNE STATE UNIVERSITY   (United States)

^b NAVAL RESEARCH LABORATORY   (United States)

^c NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(6 BENZHYDRYLTETRAHYDROPYRAN 3 YL)(1H INDOL 5 YLMETHYL)AMINE; (6 BENZHYDRYLTETRAHYDROPYRAN 3 YL)(4 AMINOBENZYL)AMINE; (6 BENZHYDRYLTETRAHYDROPYRAN 3 YL)(4 HYDROXYBENZYL)AMINE; 2 BENZHYDRYL 5 (4 HYDROXYBENZYLAMINO)TETRAHYDROPYRAN 4 OL; 2 BENZHYDRYL 5 [(1H INDOL 5 YL METHYL)AMINO]TETRAHYDROPYRAN 4 OL; 2 BENZHYDRYL 5 BENZYLAMINOTETRAHYDROPYRAN 4 OL; DOPAMINE; DOPAMINE TRANSPORTER; DULOXETINE; FLUOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; NORADRENALIN UPTAKE INHIBITOR; PYRAN DERIVATIVE; REBOXETINE; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; VANOXERINE; VENLAFAXINE;

ANIMAL TISSUE; ARTICLE; ASYMMETRIC SYNTHESIS; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENANTIOMER; HYDROGEN BOND; NEUROTRANSMISSION; NONHUMAN; PHARMACOPHORE; RAT;

ANIMALS; BENZHYDRYL COMPOUNDS; CEREBRAL CORTEX; CORPUS STRIATUM; CRYSTALLOGRAPHY, X-RAY; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MOLECULAR STRUCTURE; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PYRANS; RADIOLIGAND ASSAY; RATS; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745865926     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0601699     Document Type: Article

References (32)

1. Amara, S. G.; Kuhar, M. J. Neurotransmitter transporters: Recent progress. Annu. Rev. Neurosci. 1993, 16, 73-93.
2. Rudnick, G. Mechanisms of biogenic amine neurotransmitter transporters. In Neurotransmitter Transporters: Structure and Function, 2nd ed.; Reith, M. E. A. Ed.; Human Press: Totowa, NJ, 2002; pp 381-432.
3. Hahn, M. K.; Blakely, R. D. Monoamine transporters. Gene structure and polymorphisms in relation to psychiatric and other complex disorders. Pharmacogenomics J. 2002, 4, 217-235.
4. Heinz, A.; Mann, K.; Weinberger, D. R.; Goldman, D. Serotonergic dysfunction, negative mood states, and response to alcohol. Alcohol.: Clin. Exp. Res. 2001, 25, 487-495.
5. Klimek, V.; Stockmeier, C.; Overholser, J. Reduced levels of norepinephrine transporters in the locus coeruleus in major depression. J. Neurosci. 1997, 17, 8451-8458.
6. Robertson, D.; Flattem, N.; Tellioglu, T. Familial orthostatic tachycardia due to norepinephrine transporter deficiency. Ann. N.Y. Acad. Sci. 2001, 940, 527-543.
7. Miller, G. M.; De La Garza, R. D.; Novak, M. A.; Madras, B. K. Single nucleotide polymorphisms distinguish multiple dopamine transporter alleles in primates: implications for association with attention deficit hyperactivity disorder and other neuropsychiatric disorders. Mol. Psychiatry 2001, 6, 50-58.
8. Ozaki, N.; Goldman, D.; Kaye, W. H. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol. Psychiatry 2003, 895, 933-896.
9. Ritz, M. C.; Lamb, R. J.; Goldberg, R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-adminstration of cocaine. Science 1987, 237, 1219-1223.
10. Kuhar, M. J.; Ritz, M. C.; Boja, J. W. The dopamine hypothesis of the reinforcing properties of cocaine. Trends Neurosci. 1991, 14, 299-302.
11. Walsh, S. L.; Cunningham, K. A. Serotonergic mechanisms involved in the discriminative stimulus, reinforcing and subjective effects of cocaine. Psychopharmacology (Berlin) 1997, 130, 41-58.
12. Mateo, Y.; Budygin, E.; John, C.; Jones, S. Role of serotonin in cocaine effects in mice with reduced dopamine transporter function. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 372-377.
13. Humble, M. Noradrenaline and serotonin reuptake inhibition as clinical principles: a review of antidepressant efficacy. Acta Psychiatr. Scand. 2000, 101, 28-36.
14. Millan, M. J. The role of monoamines in the actions of established and "novel" antidepressant agents: a critical review. Eur. J. Pharmacol. 2004, 500, 371-384.
15. Carrol, F. I.; Lewin, A. H.; Mascarella, S. W. Dopamine transporter uptake blockers: structure activity relationships. In Neurotransmitter Transporters: Structure and Function. 2nd ed.; Reith, M. E. A. Ed.; Human Press: Totowa, NJ, 2002; pp 381-432.
16. Singh, S. Chemistry, design, and structure-activity relationship of cocaine antagonists. Chem. Rev. 2000, 100, 925-1024.
17. Dutta, A. K.; Zhang, S.; Kolhatkar, R.; Reith, M. E. A. Dopamine transporter as target for drug development of cocaine dependence medications. Eur. J. Pharmacol. 2003, 479, 93-106.
18. Spinks, D.; Spinks, G. Serotonin reuptake inhibition: an update on current research strategies. Curr Med Chem. 2002, 9, 799-810.
19. Wong, D. T.; Bymaster, F. P. Development of antidepressant drugs. Fluoxetine (Prozac) and other selective serotonin uptake inhibitors. Adv. Exp. Med. Biol. 1995, 363, 77-95.
20. Hiemke, C.; Hartter, S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000, 85, 11-28.
21. Owens, M. J.; Nemeroff, C. B. The serotonin transporter and depression. Depression Anxiety 1998, 8, 5-12.
22. Miller, D. K.; Wong, E. H.; Chesnut, M. D.; Dwoskin, L. P. Reboxetine: functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 2002, 302, 687-695.
23. Scates, A. C.; Doraiswamy, P. M. Reboxetine: a selective norepinephrine reuptake inhibitor for the treatment of depression. The Annals of Pharmacology 2000, 34, 1302-1312.
24. Hajos, M.; Fleishaker, J. C.; Filipiak-Reisner, J. K.; Brown, M. T.; Wong, E. H. F. The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev. 2004, 10, 23-44.
25. Koch, S.; Hemrick-Luecke, S. K.; Thompson, L. K.; Evans, D. C.; Threlkeld, P. G.; Nelson, D. L.; Perry, K. W.; Bymaster, F. P. Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats. Neuropharmacology 2003, 45, 935-944.
26. Thase, M. E.; Entsuah, A. R.; Rudolph, R. L. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br. J. Psychiatry 2001, 178, 234-241.
27. Zhang, S.; Reith, M. E. A.; Dutta, A. K. Design, synthesis, and activity of novel cis- and trans-3,6-disubstituted pyran biomimetics of 3,6-disubstituted piperidine as potential ligands for the dopamine transporter. Bioorg. Med. Chem. Lett. 2003, 13, 1591-1595.
28. Zhang, S.; Zhen, J.; Reith, M. E. A.; Dutta, A. K. Structural requirements for 2,4- and 3,6-disubstituted pyran biomimetics of cis-(6-benzhydryl-piperidin-3-yl)-benzylamine compounds to interact with monoamine transporters. Bioorg. Med. Chem. 2004, 12, 6301-6315.
29. Zhang, S.; Zhen, J.; Reith, M. E. A.; Dutta, A. K. Discovery of novel trisubstituted asymmetric pyran derivatives, (2S,4R,5R)-2-benzhydryl-5- benzylamino-tetrahydropyran-4-ol, exhibiting high affinity for serotonin and norepinephrine transporters in a stereospecific manner. J. Med. Chem. 2005, 48, 4962-4971.
30. Schmidt, B. Epoxide opening reactions of aryl substituted dihydropyran oxides: regio- and stereochemical studies directed towards deoxy-aryl-C- glycosides. J. Chem. Soc., Perkin Trans. 1, 1999, 2627-2637.
31. Chini, M.; Crotti, P.; Gardelli, C.; Macchia, F. Regiochemical control of ring opening of 1,2-epoxides by means of chelating processes. 7. Synthesis and ring-opening reactions of cis- and trans-oxides derived from 2-(benzyloxy)-3,6-dihydro-2H-pyran. J. Org. Chem. 1994, 59, 4131-4137.
32. Vogel, A. I. Vogel's Textbook of Practical Organic Chemistry, 5th ed.; Longman Scientific & Technical: Harlow, England, 1989.